The news is directly related to Lazard and is likely to influence investor sentiment. While the Overweight rating suggests that Morgan Stanley expects the stock to outperform, the reduction in price target may create some uncertainty. However, the impact on the stock price is likely to be neutral in the short term as the reduction is relatively small.